Lucid Diagnostics Inc（LUCD）の株式分析LUCDLucid Diagnostics Inc

Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company's products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The Company is a subsidiary of PAVmed Inc. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Lucid Diagnostics Inc is not a good buy right now due to its extremely low RSI of 14.018, indicating oversold conditions, and a staggering year-to-date change of -57.32%. The stock is currently trading at $0.48, significantly below its analyst price target of $3, but the risks are substantial with a negative gross margin of -5.16% in Q2 2026 and ongoing losses.